Stockscreener 앱 받기
7.853
9.15%
0.643
전일 마감가:
$7.21
열려 있는:
$7.25
하루 거래량:
219.81K
Relative Volume:
0.47
시가총액:
$224.54M
수익:
$67.22M
순이익/손실:
$-65.78M
주가수익비율:
-3.2903
EPS:
-2.3867
순현금흐름:
$-79.02M
1주 성능:
+15.40%
1개월 성능:
-5.18%
6개월 성능:
+15.74%
1년 성능:
-34.58%
1일 변동 폭
$7.25
$7.95
1주일 범위
$6.71
$7.95
52주 변동 폭
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.90 | 204.93M | 67.22M | -65.78M | -79.02M | -2.3867 |
VRTX
Vertex Pharmaceuticals Inc
|
441.38 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.39 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
829.13 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.38 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.21 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | B. Riley Securities | Buy |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-10-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - BioSpace
mRNA drug maker Arcturus hits Jefferies 2026 healthcare stage in New York - Stock Titan
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating - Moomoo
How (ARCT) Movements Inform Risk Allocation Models - Stock Traders Daily
Arcturus Therapeutics unveils OTC deficiency research at SIMD 2026 Annual Meeting - Traders Union
Arcturus Therapeutics Holdings Inc (NQ: ARCT - FinancialContent
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - MSN
ARCTURUS THERAPEUTICS HOLDINGS INC UPSWING STARTED | ARCT STOCK NEWS (VWpPDIK5Ud) - fathomjournal.org
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Guggenheim Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating - Moomoo
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
MSN Money - MSN
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Arcturus Therapeutics (ARCT) Reports Progress in Q1 2026 Earnings Call - GuruFocus
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress - BioSpace
ARCT Should I Buy - Intellectia AI
Earnings call transcript: Arcturus Therapeutics Q1 2026: EPS Beat, Revenue Decline - Investing.com
Trading Systems Reacting to (ARCT) Volatility - Stock Traders Daily
ARCT: Advanced rare disease pipeline, reduced expenses, and strong cash position support 2026 milestones - TradingView
ARCT: Achieved key clinical milestones in rare disease mRNA programs with strong financial runway - TradingView
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), eff - Bitget
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline - TipRanks
Arcturus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances - ChartMill
Arcturus Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Arcturus Therapeutics (ARCT) CFO granted 100,000 stock options - Stock Titan
[Form 3] Arcturus Therapeutics Holdings Inc. Initial Statement of Beneficial Ownership - Stock Titan
Q1 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript - GuruFocus
Arcturus Therapeutics (NASDAQ: ARCT) Q1 2026 hit by 93% revenue drop - Stock Titan
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Revenue plunge and leadership change at Arcturus (NASDAQ: ARCT) - Stock Titan
ARK/ Cathie Wood report 2.95M shares in Arcturus (ARCT) - Stock Titan
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2026 Earnings Repor - GuruFocus
Arcturus Therapeutics Holdings Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving AverageTime to Sell? - MarketBeat
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78 - MSN
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May - PharmiWeb.com
Press Release: Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - 富途牛牛
Arcturus plans after-hours results and a 4:30 p.m. ET call May 7 - Stock Titan
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - marketscreener.com
How Arcturus Therapeutics Holdings Inc. (ARCT) Affects Rotational Strategy Timing - Stock Traders Daily
ARCT Price Today: Arcturus Therapeutics Holdings Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Arcturus (NASDAQ: ARCT) schedules 2026 virtual meeting on pay, board and auditor - Stock Titan
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
1.91%
자본화:
|
볼륨(24시간):